Global Hunter Securities Starts Amylin Pharmaceuticals (AMLN) at Accumulate; Bydureon Launch, Ramp Critical to Long-Term Upside
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Global Hunter Securities initiates coverage on Amylin Pharmaceuticals (NASDAQ: AMLN) with a Accumulate. PT $14.00.
Global analyst said, "MLN is a leader in the development of novel drugs for diabetes and metabolic disorders. The company’s main value driver is Bydureon, for type II diabetes. AMLN is awaiting a January 28, 2012 PDUFA date for the drug; if approved, we expect a 1Q12 launch. AMLN also has two marketed products: Byetta, for type II diabetes, and Symlin, for both type I and type II diabetes. Bydureon and Byetta are novel formulations of exenatide, an analog of naturally occurring glucagon-like peptide 1 (GLP-1). We expect Bydureon to compare favorably to alternative GLP-1 therapies. Following the expected launch of Bydureon, we estimate that the combined US annual sales of exenatide-based products could approach $1.7B in 2018. Longer-term drivers for AMLN shares include a formulation of exenatide intended for monthly dosing, and metreleptin, for lipodystrophy."
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $10.79 yesterday.
Global analyst said, "MLN is a leader in the development of novel drugs for diabetes and metabolic disorders. The company’s main value driver is Bydureon, for type II diabetes. AMLN is awaiting a January 28, 2012 PDUFA date for the drug; if approved, we expect a 1Q12 launch. AMLN also has two marketed products: Byetta, for type II diabetes, and Symlin, for both type I and type II diabetes. Bydureon and Byetta are novel formulations of exenatide, an analog of naturally occurring glucagon-like peptide 1 (GLP-1). We expect Bydureon to compare favorably to alternative GLP-1 therapies. Following the expected launch of Bydureon, we estimate that the combined US annual sales of exenatide-based products could approach $1.7B in 2018. Longer-term drivers for AMLN shares include a formulation of exenatide intended for monthly dosing, and metreleptin, for lipodystrophy."
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $10.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Canaccord Starts Galiano Gold (GAU:CN) at Buy
- Alliance Global Partners Starts Momentus (MNTS) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
